IL-13 Variant

Product Information
Primary Accession	P35225
Species	Human
Sequence	Gly35-Asn146
Purity	> 97% as analyzed by SDS-PAGE > 97% as analyzed by HPLC
Endotoxin Level	< 1 EU/ µg of protein by LAL method
Biological Activity	Fully biologically active when compared to standard. The ED₅₀ as determined by a cell proliferation assay using human TF-1 cells is less than 0.5 ng/ml, corresponding to a specific activity of > 2.0 × 10⁶ IU/mg.
Expression System	E. coli
Theoretical Molecular Weight	12.3 kDa
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.2, 5% trehalose.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Additional Information
Other Names	Interleukin-13, IL-13, IL13, NC30
Target Background	The human IL-13 cDNA encodes a 132 amino acid protein containing a proposed 20 amino acid signal peptide. Human IL-13 shares approximately 30% amino acid sequence homology to human IL-4 and the two cytokines exhibit overlapping biological activities. Human IL-13 is produced by activated Th0, Th1-like Th2-like and CD8 T cells. Similarly to IL-4, IL-13 has multiple effects on the differentiation and functions of monocytes/macrophages. IL-13 can suppress the cytotoxic functions of monocytes/macrophages. It can also suppress the production of proinflammatory cytokines and upregulate the production of IL-1ra by monocytes/macrophages.